Arbutus Escalates LNP Patent War, Leveraging $178M Moderna Precedent to Pressure Pfizer

Arbutus BioPharma Escalates mRNA Vaccine Patent Litigation

Arbutus BioPharma has escalated its long-standing legal efforts by filing three new patent infringement lawsuits against Pfizer and BioNTech in Europe and Canada. These actions allege that the companies' COVID-19 vaccines infringe on Arbutus's patents related to lipid nanoparticle technology, crucial for vaccine delivery. This expansion follows an ongoing U.S. suit and a significant multibillion-dollar settlement with Moderna earlier this year over similar claims, from which Arbutus recently received a $178 million payment. The lawsuits aim to prove patent violations in the use of this key technology.

• Arbutus BioPharma has significantly broadened its legal campaign against Pfizer and BioNTech by initiating three new patent infringement lawsuits across various European countries and Canada. These new legal actions extend the scope of an existing U.S. lawsuit, which contends that the COVID-19 vaccines developed by Pfizer and BioNTech unlawfully utilize Arbutus's patented lipid nanoparticle technology for vaccine delivery. This strategic move aims to enforce intellectual property rights on a global scale.
• The current lawsuits are underpinned by Arbutus's prior success in similar litigation, notably a multibillion-dollar settlement reached with Moderna earlier this year concerning its mRNA vaccines. This precedent highlights the potential financial liabilities for Pfizer and BioNTech. As part of the Moderna settlement, Arbutus recently received a payment of $178 million, demonstrating the tangible value and enforceability of its lipid nanoparticle technology patents.
• At the heart of Arbutus's legal challenge is the alleged infringement of its proprietary lipid nanoparticle (LNP) technology. This technology is fundamental to the efficacy of mRNA vaccines, as it enables the safe and efficient delivery of genetic material into human cells, prompting the body to produce antigens and mount an immune response against pathogens like SARS-CoV-2. The lawsuits assert that Pfizer and BioNTech's vaccines leverage this patented delivery system without authorization.

The Persistent Global Burden of COVID-19

Based on data from 2024-2025, the COVID-19 pandemic has resulted in over 770 million confirmed infections and approximately 7.0 million deaths worldwide. While the World Health Organization (WHO) declared an end to the public health emergency of international concern on May 5, 2023, the disease is expected to remain a long-term global health consideration. This persistent threat is driven by the continued mutation of SARS-CoV-2, which gives rise to new variants. In a monumental global public health response, healthcare authorities have administered more than 13 billion vaccine doses.

More granular data from specific regions illustrates the ongoing, albeit diminished, impact of the virus. In Poland, 381,244 cases and 4,329 deaths were recorded throughout 2023. Although the country's COVID-19 mortality rate was several times lower than in 2022, the disease still accounted for more deaths than other infectious diseases. Furthermore, evidence suggests that official figures may underestimate the true burden of the disease. A US-based analysis covering March 2020 to July 2022 estimated 1,168,481 total deaths, significantly higher than the 1,022,147 recorded from death certificates alone, with the most severe undercounting observed in the 18-49 age group.

Key Safety Signals from COVID-19 Clinical Trials

Clinical trials for various COVID-19 therapies have elucidated the safety profiles of a wide range of agents, from antivirals to immunomodulators. While many treatments demonstrate a favorable safety profile, post-marketing surveillance and specific studies have identified key adverse events and signals of interest for certain drug classes.

• Nirmatrelvir/ritonavir: This agent is associated with a significant signal for disease recurrence (ROR: 212.01; 95% CI: 162.85-276.01), a signal not detected for other COVID-19 drugs. The most frequently reported non-serious events include disease recurrence (40.43%), dysgeusia (17.55%), and diarrhea (8.80%), with an overall low risk of serious adverse events.

• IL-6 Inhibitors: Evidence regarding adverse events for IL-6 inhibitors like tocilizumab and sarilumab is of low to moderate certainty. For tocilizumab, studies suggest little to no difference in AE risk (RR 1.03), with no new safety signals observed. For sarilumab, evidence on adverse and serious adverse events remains uncertain (RR 1.12 and RR 1.09, respectively).

• Antivirals and Monoclonal Antibodies: In general, antivirals (favipiravir, molnupiravir, remdesivir, nirmatrelvir-ritonavir) show a good safety profile with no significant difference in serious or non-serious adverse events. Direct comparison between remdesivir and sotrovimab found comparable rates of adverse events (OR = 0.98), though sotrovimab was associated with a lower rate of AEs in solid organ transplant recipients (OR, 0.15).

• mRNA Vaccines: When compared to influenza vaccines, mRNA COVID-19 vaccines were linked to more systemic reactions (e.g., myalgia, fatigue) but fewer neurological events like syncope or Guillain-Barre syndrome. The mRNA vaccines showed a higher risk for manageable cardiovascular complications, including hypertensive crisis (adjusted ROR, 12.72) and supraventricular tachycardia (adjusted ROR, 7.94).

• Other Investigated Agents: Several other therapies demonstrated favorable safety in trials. The monoclonal antibody adintrevimab, atorvastatin with aspirin, and the traditional medicine Hua Shi Bai Du Granule (Q-14) were not associated with excess or serious adverse events in their respective studies.

• Special Populations: In a study of breast cancer patients receiving antitumor therapy after a COVID-19 diagnosis, no increased risk of overall or serious treatment-related adverse events was observed. The most common AEs in this cohort were peripheral neuropathy (29.4%), pain (26.6%), and fatigue (25.7%).

Efficacy and Outcomes of Approved COVID-19 Therapies

Recent large-scale evidence from 2024 has solidified the role of remdesivir in improving survival for adults hospitalized with COVID-19. In a cohort of over 169,000 patients, remdesivir initiation was associated with significantly lower 14-day and 28-day mortality rates compared to no antiviral treatment, with adjusted hazard ratios around 0.75-0.79 across different oxygen-dependency strata. This builds upon earlier, more cautious 2021 meta-analyses which concluded that while remdesivir could accelerate clinical improvement and discharge, a survival benefit was not clearly established at that time. Other direct-acting antivirals, namely nirmatrelvir/ritonavir and molnupiravir, have also been shown to reduce severe outcomes, as confirmed by nationwide data from South Korea. A 2021 meta-analysis further supports the benefit of the antiviral class, finding it provided a distinct advantage in clinical improvement (RR 1.11) and was associated with a lower rate of serious adverse events (RR 0.75) compared to control groups.

The evidence for immunomodulators and other repurposed drugs has been more varied. Corticosteroids have consistently demonstrated a mortality benefit in patients with more severe disease. A 2021 network meta-analysis reported that corticosteroids significantly reduced mortality (OR = 0.84) and improved cure rates (OR = 1.17). Data from South Korea likewise showed immunomodulators such as dexamethasone and tocilizumab improved recovery in severe cases. In contrast, several agents investigated early in the pandemic were found to be ineffective or harmful. Multiple 2021 analyses concluded that chloroquine and hydroxychloroquine provided no significant therapeutic effect and were not recommended. In fact, one network meta-analysis found that high-dose chloroquine was associated with an increased risk of mortality (OR = 3.20) and adverse events. Other antivirals such as lopinavir/ritonavir and interferons were also found to lack efficacy or increase the risk of adverse events in hospitalized patients.

Outcomes in specific patient populations highlight the interplay between COVID-19, underlying conditions, and treatment. A 2022 study of follicular lymphoma patients treated with obinutuzumab-based immunochemotherapy reported a high overall response rate of 93.8% and an 18-month overall survival of 88%. Among patients who contracted SARS-CoV-2, outcomes differed significantly by chemotherapy backbone, with all G-CHOP patients recovering versus four deaths among 12 G-bendamustine patients. For rheumatology patients on rituximab, COVID-19 was associated with a high mortality rate of 27.0%, a risk significantly increased by comorbidities but markedly reduced by vaccination (OR: 0.170). The broader protective effect of vaccination was confirmed in a 2024 study of hospitalized patients, where complete vaccination was linked to shorter hospitalizations (5.25 vs. 6.11 days) and significantly lower rates of ICU admission, intubation, and mortality.